Zhou R, et al. - Since tumour-infiltrating immune cells are a source of important prognostic information for patients with resectable colon cancer, researchers performed systematic assessments of the immune landscape inferred from bulk tumor transcriptomes of stage I–III colon cancer patients and put forth a novel immune model. They proposed a diagnostic model, designated the diagnostic immune risk score (dIRS) and a prognostic immune risk score (pIRS). dIRS showed high specificity and sensitivity in both the training and validation sets. Improved accuracy of relapse risk prediction was seen with the integration of the pIRS with clinical characteristics in a composite nomogram. This offered a higher net benefit than TNM stage, with well-fitted calibration curves. Overall, for diagnosis and prognosis prediction of colon cancer, the proposed dIRS and pIRS models hold promise as novel signatures.